Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
A simple clinical biomarker—having received a prior CDK4/6 inhibitor for over 12 months—identifies patients likely to achieve significant progression-free survival (nearly nine months) with single-agent elacestrant. This allows clinicians to select patients for monotherapy without complex genomic profiling.
Related Insights
The novel DiviTum TKA assay measures cell proliferation in real-time. Patterns of TKA level suppression, rebound, or lack of suppression within the first month of CDK4/6 inhibitor therapy strongly predict a patient's long-term progression-free survival, offering an early look at treatment efficacy.
A patient's time to progression on first-line CDK4/6 inhibitor therapy acts as an informal biomarker. A shorter duration, such as 14 months, is viewed by experts as "not so great" and indicates a degree of underlying endocrine resistance that influences subsequent treatment strategies.
The ELEGANT trial uses a "switch strategy," introducing elicestrin only after 2-5 years of standard therapy. This design pragmatically adapts to the evolving clinical landscape where CDK4/6 inhibitors are now standard initial treatment, ensuring the trial's relevance by testing the drug in a post-CDK4/6 inhibitor setting.
Post-approval, real-world analyses have validated the efficacy of elacestrant seen in the pivotal EMERALD trial. This confirmation shows that the clinically meaningful progression-free survival of 6-8 months is achievable in routine clinical practice, boosting clinician confidence.
While PI3K pathway alterations are linked to a poor prognosis, real-world data provides reassurance for a common clinical dilemma. Patients with co-mutations in both ESR1 and PI3K pathways still achieve significant benefit from elacestrant monotherapy, with progression-free survival (5.2-6.3 months) comparable to the overall population in the pivotal EMERALD trial.
Post-approval studies of the oral SERD elacestrant confirm its clinical benefit in ESR1-mutant breast cancer. However, this real-world evidence also reveals a new insight: patients who have both an ESR1 and a PIK3CA mutation tend to have a shorter time on treatment, suggesting that the PIK3CA mutation may drive resistance to this therapy.
Data from multiple trials (EMERALD, VERITEC-2) reveal that the duration of a patient's response to a prior CDK4/6 inhibitor acts as a key predictive biomarker. Patients who benefited from CDK4/6 inhibitors for longer periods (e.g., >12-18 months) subsequently experienced a significantly greater progression-free survival benefit from oral SERD therapy.
Large real-world databases show elacestrant monotherapy achieves a median time-to-next-treatment of over 8 months. This impressive outcome aligns with the most favorable subgroup from the pivotal EMERALD trial (patients on prior CDK4/6i >12 months), suggesting that clinicians are successfully identifying the ideal candidates for this therapy in routine practice.
Data from the MONARCH-E and NATALY trials show that the benefit of adjuvant CDK4/6 inhibitors like abemaciclib and ribociclib persists and even increases after patients complete their 2-3 year treatment course. This sustained "carryover effect" suggests a lasting impact on disease biology rather than just temporary suppression.
Before CDK inhibitors, second-line fulvestrant provided ~12 months of progression-free survival (PFS). Now, after progression on a CDK inhibitor, PFS on fulvestrant is merely 2-3 months. This demonstrates how a powerful frontline therapy can alter a tumor's genomic structure, making it more virulent and resistant to subsequent standard treatments.
